Met409-Cys662 with His Tag at C-Terminus
PBS, PH7.4,5% trehalose
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1.Thompson EW, et al. (1994) Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat. 31(2-3): 357-70.
2.Jezierska A, et al. (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15(2): RA32-40.
3.Fredrich M, et al. (2010) MMP-2 is involved in synaptic remodeling after cochlear lesion. Neuroreport. 21(5): 324-7.
Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades extracellular matrix components, playing a pivotal role in cell migration during physiological and pathological processes. Its expression is regulated by EMMPRIN, Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation requires MT1-MMP and TIMP-2. Low MMP-2 levels are associated with a favorable prognosis in hormone receptor-negative tumors, which are typically high-risk. As a zymogen requiring proteolytic activation, MMP-2 is broadly implicated in cancer invasion and metastasis, including human breast cancer. Blocking MMP-2 secretion and activation during breast carcinoma development may reduce metastasis. The detection of active MMP-2 or the ratio of pro-MMP-2 to active MMP-2 is a highly sensitive indicator of cancer metastasis. Modulating MMP-2 expression and activation via specific inhibitors or activators offers a promising therapeutic strategy for breast cancer treatment.
1μg (R: reducing condition, N: non-reducing condition).
The purity of MMP-2 His Tag Protein, Mouse is more than 95% determined by SEC-HPLC.